BACKGROUND: Anticonvulsant medications are commonly used for off-label indications. However, managed care organizations can restrict utilization of medication to indicated uses only. OBJECTIVE: To evaluate the pattern of off-label use of second-generation anticonvulsants after implementing a formulary change. METHODS: We did a retrospective analysis of an administrative pharmacy claims database for a managed care plan with more than 1 million members continuously enrolled during 2004-2005. The study evaluated off-label use and explored pharmacy utilization patterns (by physician specialty, region, plan type, age, sex, copayment) across the study population following the formulary change. RESULTS: A total of 10,185 patients had at least 1 pharmacy claim (total of 137,638 claims) for a second-generation anticonvulsant during the study period. Most members were female (68%), and 4.9% were <18 years old. A total of 3986 of 4698 patients (84.8%) and 4600 of 5487 patients (83.8%) had anticonvulsants prescribed for off-label use in 2004 and 2005, respectively (P = .162). The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005 (P <.050), which may have been because of the change to nonpreferred coverage. Primary care physicians accounted for 41.3% of the prescribing of second-generation anticonvulsants for off-label uses, followed by neurologists (9.4%), psychiatrists (2.8%), and other (46.5%). The coverage change resulted in cost savings for the plan of $0.16 per member per month. CONCLUSIONS: The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005. Future considerations for controlling off-label use may include requiring prior authorization and provider education.
BACKGROUND: Anticonvulsant medications are commonly used for off-label indications. However, managed care organizations can restrict utilization of medication to indicated uses only. OBJECTIVE: To evaluate the pattern of off-label use of second-generation anticonvulsants after implementing a formulary change. METHODS: We did a retrospective analysis of an administrative pharmacy claims database for a managed care plan with more than 1 million members continuously enrolled during 2004-2005. The study evaluated off-label use and explored pharmacy utilization patterns (by physician specialty, region, plan type, age, sex, copayment) across the study population following the formulary change. RESULTS: A total of 10,185 patients had at least 1 pharmacy claim (total of 137,638 claims) for a second-generation anticonvulsant during the study period. Most members were female (68%), and 4.9% were <18 years old. A total of 3986 of 4698 patients (84.8%) and 4600 of 5487 patients (83.8%) had anticonvulsants prescribed for off-label use in 2004 and 2005, respectively (P = .162). The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005 (P <.050), which may have been because of the change to nonpreferred coverage. Primary care physicians accounted for 41.3% of the prescribing of second-generation anticonvulsants for off-label uses, followed by neurologists (9.4%), psychiatrists (2.8%), and other (46.5%). The coverage change resulted in cost savings for the plan of $0.16 per member per month. CONCLUSIONS: The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005. Future considerations for controlling off-label use may include requiring prior authorization and provider education.
Authors: Danni Zhao; Divya Shridharmurthy; Matthew J Alcusky; Yiyang Yuan; Anthony P Nunes; Anne L Hume; Jonggyu Baek; Kate L Lapane Journal: Drugs Aging Date: 2020-02 Impact factor: 3.923
Authors: Marie-Laure Laroche; Thi Hong Van Ngo; Caroline Sirois; Amélie Daveluy; Michel Guillaumin; Marie-Blanche Valnet-Rabier; Muriel Grau; Barbara Roux; Louis Merle Journal: Eur Geriatr Med Date: 2021-03-20 Impact factor: 1.710
Authors: Christine Leong; Muhammad M Mamdani; Tara Gomes; David N Juurlink; Erin M Macdonald; Marina Yogendran Journal: Neurology Date: 2016-02-05 Impact factor: 9.910
Authors: Lidia M V R Moura; Jason R Smith; Zhiyu Yan; Deborah Blacker; Lee H Schwamm; Joseph P Newhouse; Sonia Hernandez-Diaz; John Hsu Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-02 Impact factor: 2.890